Alta Sciences

DECEMBER 29, 2023

PBSS—ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices lperez Fri, 12/29/2023 - 16:20 Image GettyImages-1075448458.jpg jpg Synopsis Foster City, CA URL [link] Event End Date Fri, 01/19/2024 - 12:00 Event Start Date Fri, 01/19/2024 - 12:00 Weight 1

Small Molecule 40

Small Molecule 40

Drug Target Review

APRIL 7, 2025

Haemoglobin A1c (HbA1c) is a validated surrogate endpoint for the reduction of microvascular complications associated with diabetes mellitus; reduced HIV-RNA levels serve as an endpoint for HIV disease control; and a reduction in low-density lipoprotein (LDL) cholesterol is used as an endpoint indicating lower likelihood of cardiovascular events.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

The Strateos Blog: Drug Discovery

MARCH 18, 2022

Strateos had the pleasure of participating at the PharmaIQ Live: Smartlab Digital 2022 conference held between March 8-9th, which focused on the potential of Lab 4.0 strategies to increase the speed, efficiency and reduce the cost of the drug discovery process. John Harman, Sr.

Small Molecule 52

Small Molecule Laboratories Production Drugs 52

The Strateos Blog: Drug Discovery

FEBRUARY 22, 2022

Strateos’ SVP of Strategy and Operations, Daniel Sipes, gave a presentation outlining how the challenges in conventional design, make, test and analyze (DMTA) cycles in small molecule drug discovery workflows can be overcome with automated end-to-end solutions from synthesis to biological testing.

Small Molecule 52

Small Molecule Science Laboratories Production 52

Alta Sciences

JANUARY 6, 2025

PBSS San Francisco BaySmall-Molecule Formulation for Discovery & Early Development iianiro Tue, 01/07/2025 - 02:44 Image GettyImages-1485218264.jpg jpg URL [link] Event End Date Wed, 01/22/2025 - 12:00 Event Start Date Wed, 01/22/2025 - 12:00 Weight 1

Small Molecule 40

Small Molecule 40

LifeSciVC

JANUARY 16, 2024

Small molecule GLP1s? Still may be some merit if they are clinical-stage and can achieve once-daily dosing without too steep a cut in efficacy or worsened adverse events vs. peptides, but be wary of the intensely competitive landscape. small molecules continue to be enthusiastically funded even at the discovery stage.

Small Molecule 142

Small Molecule Trials Therapies Disease 142

The Pharma Data

JANUARY 19, 2021

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel orally administered first-in-class small molecule that was developed based on an anti-virulence approach targeting Staphylococcus aureus including MRSA. About ALS-4.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. View original content: [link]. SOURCE Sosei Heptares. Source link.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Atomwise Blog

MARCH 9, 2022

At the American Chemical Society Spring National Meeting & Expo, Atomwise members were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Spring 2022 National Meeting for other presentation sessions.

Small Molecule 52

Small Molecule Research 52

Drug Target Review

SEPTEMBER 25, 2024

At TOLREMO, we have developed a proprietary modular phenotypic screening platform that leverages transcriptional reprogramming events associated with non-genetic resistance to deliver new chemical scaffolds and identify novel resistance regulators. Inhibiting KDM5A, a regulator of cell proliferation, poses another interesting approach.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

DrugBank

OCTOBER 17, 2024

By utilizing high-resolution protein structures obtained through X-ray crystallography, researchers could design small molecules that potently inhibit the SARS-CoV-2 main protease, a key enzyme essential for viral replication.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

The Pharma Data

DECEMBER 20, 2020

ALS-4 is a novel small molecule adopting an anti-virulence (non-antibiotic) approach to address the growing unmet medical needs of infections caused by Staphylococcus aureus. Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers. About ALS-4.

Small Molecule 40

Small Molecule Clinical Trials Trials Treatment 40

Zobio

MARCH 12, 2024

In person Every year ZoBio is actively participating in the Drug Discovery Chemistry event hosted by the Cambridge Healthtech Institute. This event serves as a premier gathering for medicinal chemists in the pharmaceutical and biotech industries, focusing on the challenges and advancements in small molecule drug discovery and optimization.

Small Molecule 40

Small Molecule Drugs Pharmaceuticals 40

Zobio

MARCH 9, 2023

In person Over the past years Cambridge Healthtech Institute’s Annual Drug Discovery Chemistry has grown to one of the largest events for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists.

Small Molecule 40

Small Molecule Drugs 40

LifeSciVC

APRIL 24, 2024

If adverse events are anticipated, it is important to understand gene dosage for such an effect (e.g., and whether a molecule’s pharmacology can help to mitigate safety risk. and whether a molecule’s pharmacology can help to mitigate safety risk. loss of function” (LoF) effect, but can also be quite nuanced (e.g.,

Production 124

Production Small Molecule Regulations Trials 124

Dark Matter Blog

JUNE 21, 2023

Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

Zobio

MARCH 12, 2024

In person Every year ZoBio is actively participating in the Drug Discovery Chemistry event hosted by the Cambridge Healthtech Institute. This event serves as a premier gathering for medicinal chemists in the pharmaceutical and biotech industries, focusing on the challenges and advancements in small molecule drug discovery and optimization.

Small Molecule 40

Small Molecule Drugs Pharmaceuticals 40

Zobio

MARCH 12, 2024

In person Every year ZoBio is actively participating in the Drug Discovery Chemistry event hosted by the Cambridge Healthtech Institute. This event serves as a premier gathering for medicinal chemists in the pharmaceutical and biotech industries, focusing on the challenges and advancements in small molecule drug discovery and optimization.

Small Molecule 40

Small Molecule Drugs Pharmaceuticals 40

Zobio

MARCH 9, 2023

In person Over the past years Cambridge Healthtech Institute’s Annual Drug Discovery Chemistry has grown to one of the largest events for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists.

Small Molecule 40

Small Molecule Drugs 40

The Pharma Data

JANUARY 13, 2021

Preliminary analyses showed no clinically meaningful differences in safety results between the dexpramipexole and placebo groups, with no serious adverse events and 96% of subjects completing the primary assessment phase. Dexpramipexole was well tolerated by patients at all doses tested. President and CEO of Knopp. ABOUT ORAL DEXPRAMIPEXOLE.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

BMG Labtech

NOVEMBER 21, 2023

Effectors of signal transmission events Second messengers are small molecules or ions that transmit signals received at the cell surface to the inside environment of the cell (Fig.

Small Molecule 40

Small Molecule Regulations Research Cell Biology 40

The Pharma Data

NOVEMBER 26, 2020

As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS ® small molecule nanoparticle technology non-GMP lines. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! ” Prof.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

Dark Matter Blog

JULY 16, 2021

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Target Review

MAY 6, 2024

We discovered that transcriptional reprogramming events are an early survival strategy cancer cells use to buy time until they are fully drug-resistant and drive clinical relapses. We found that, indeed, cancer’s earliest defence mechanisms are triggered almost immediately after exposure to a targeted cancer therapy.

Therapies 105

Therapies Science Small Molecule Clinical Trials 105

Drug Target Review

JUNE 12, 2023

The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

Zobio

SEPTEMBER 12, 2024

This five-day Medicinal Chemistry School, organized by the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society , focuses on the most cutting-edge aspects of small molecule drug discovery, highlighting.

Small Molecule 40

Small Molecule Drugs 40

Zobio

SEPTEMBER 12, 2024

This five-day Medicinal Chemistry School, organized by the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society , focuses on the most cutting-edge aspects of small molecule drug discovery, highlighting.

Small Molecule 40

Small Molecule Drugs 40

The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

Progress from target ID through to IND submission in conventional workflows can take upwards of 6+ years, where success hinges on iterative cycles of DMTA.

Biochemical Assays 52

Biochemical Assays Small Molecule Laboratories Science 52

The Strateos Blog: Drug Discovery

SEPTEMBER 24, 2021

OVERCOMING BOTTLENECKS IN TRADITIONAL WORKFLOWS Conventional small molecule drug discovery workflows take upwards of 6 years to progress from target ID through to IND submission with key medicinal chemistry (MedChem) steps involved in lead generation. Ben Miles, Ph.D.,

Synthetic Chemistry 52

Synthetic Chemistry Small Molecule Production Science 52

The Pharma Data

JANUARY 5, 2021

The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. An archived replay of the webcast will be available for at least 30 days following the presentation. About Relay Therapeutics.

Small Molecule 40

Small Molecule Therapies Drugs 40

The Pharma Data

OCTOBER 27, 2020

Mirati is advancing a novel pipeline to treat large patient populations across multiple programs and tumor types, including two programs, adagrasib and sitravatinib, in registration-enabling studies to treat non-small cell lung cancer (NSCLC). View original content to download multimedia: [link]. SOURCE Mirati Therapeutics, Inc.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., Additional study treatment-related adverse events reported by ?2% versus 38.9%). .” versus 38.9%). versus 31.2%).

Therapies 52

Therapies FDA Approval Treatment Small Molecule 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

OCTOBER 14, 2020

Live Webcast : accessible from the Company’s website at www.eloxxpharma.com under Events and Presentations or with this link: [link]. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. Conference ID : 9467336.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

Advarra

FEBRUARY 24, 2023

But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? Also known as a clinical event committee (CEC), EAC members evaluate a clinical event in the context of the protocol and the individual participant’s medical information.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52